Ortho Biotech Clinical Affairs, L.L.C.
16
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
56.3%
9 terminated/withdrawn out of 16 trials
40.0%
-46.5% vs industry average
19%
3 trials in Phase 3/4
150%
9 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
Role: collaborator
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
Role: collaborator
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Role: collaborator
Effects of Exercise in Combination With Epoetin Alfa
Role: collaborator
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
Role: collaborator
Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer
Role: collaborator
Prevalence and Treatment of Anemia in Rehabilitation Patients
Role: collaborator
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
Role: collaborator
The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery
Role: collaborator
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Role: collaborator
A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
Role: collaborator
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Role: collaborator
Epoetin Alfa for HIV-Associated Neuropathy Trial
Role: collaborator
PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy
Role: collaborator
Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)
Role: collaborator
Treatment of Chronic Anemia With Epoetin Alfa in Elderly
Role: collaborator
All 16 trials loaded